Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CITIZENS FINANCIAL GROUP INC/RICFG · Entity 1913 | Director | February 14, 2019 | February 15, 2019 |
| REGENERON PHARMACEUTICALS, INC.REGN · Entity 2010 | Director | July 02, 2026 | July 07, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CITIZENS FINANCIAL GROUP INC/RI
Report date February 14, 2019 · Filed February 15, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 60,993.604 |
Reported balance
After 2019-02-14 transaction · row 1
1 source rowRow 1 · 2019-02-14 · Grant · Acquired 30.91 · Balance 60,993.604 F1: Reflects restricted stock units credited to the reporting person's account following the issuer's dividend payment, pursuant to an award granted to the filer pursuant to the Citizens Financial Group, Inc. 2014 Non-Employee Directors Compensation Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects restricted stock units credited to the reporting person's account following the issuer's dividend payment, pursuant to an award granted to the filer pursuant to the Citizens Financial Group, Inc. 2014 Non-Employee Directors Compensation Plan.
REGENERON PHARMACEUTICALS, INC.
Report date July 02, 2026 · Filed July 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 17,303 |
Reported balance
After 2026-07-02 transaction · row 1
1 source rowRow 1 · 2026-07-02 · Sale · Disposed 200 · Balance 17,303 F1: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025. F2: Represents volume-weighted average price of sales of 200 shares of Company stock on July 2, 2026 at prices ranging from $650.10 to $650.19. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on July 2, 2026 at each separate price. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025.
F2: Represents volume-weighted average price of sales of 200 shares of Company stock on July 2, 2026 at prices ranging from $650.10 to $650.19. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on July 2, 2026 at each separate price.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 01, 2024 Filed Mar 5, 2024 21:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 2 | $975.70 | $1,951.40 |
DisclosureSEC source: 0001968202-24-000084 · edgardoc.xml · nonDerivative · entry 8 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,369 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 21:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1 | $974.78 | $974.78 |
DisclosureSEC source: 0001968202-24-000084 · edgardoc.xml · nonDerivative · entry 7 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,371 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 21:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 2 | $972.29 | $1,944.58 |
DisclosureSEC source: 0001968202-24-000084 · edgardoc.xml · nonDerivative · entry 6 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,372 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 21:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1 | $971.75 | $971.75 |
DisclosureSEC source: 0001968202-24-000084 · edgardoc.xml · nonDerivative · entry 5 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,374 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 21:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 4 | $970.38 | $3,881.52 |
DisclosureSEC source: 0001968202-24-000084 · edgardoc.xml · nonDerivative · entry 4 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,375 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 21:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1 | $969.18 | $969.18 |
DisclosureSEC source: 0001968202-24-000084 · edgardoc.xml · nonDerivative · entry 3 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,379 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 21:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1 | $968.66 | $968.66 |
DisclosureSEC source: 0001968202-24-000084 · edgardoc.xml · nonDerivative · entry 2 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,380 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 21:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1 | $967.50 | $967.50 |
DisclosureSEC source: 0001968202-24-000084 · edgardoc.xml · nonDerivative · entry 1 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,381 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023. Read SEC document |
| February 01, 2024 Filed Feb 5, 2024 21:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 4 | $963.73 | $3,854.92 |
DisclosureSEC source: 0001968202-24-000048 · edgardoc.xml · nonDerivative · entry 21 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,382 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023. F19 · price: Represents volume-weighted average price of sales of 4 shares of Company stock on February 1, 2024 at prices ranging from $963.54 to $963.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 1, 2024 at each separate price. Read SEC document |
| February 01, 2024 Filed Feb 5, 2024 21:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 6 | $962.49 | $5,774.94 |
DisclosureSEC source: 0001968202-24-000048 · edgardoc.xml · nonDerivative · entry 20 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,386 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023. F18 · price: Represents volume-weighted average price of sales of 6 shares of Company stock on February 1, 2024 at prices ranging from $962.20 to $962.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 1, 2024 at each separate price. Read SEC document |
| February 01, 2024 Filed Feb 5, 2024 21:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 4 | $961.37 | $3,845.48 |
DisclosureSEC source: 0001968202-24-000048 · edgardoc.xml · nonDerivative · entry 19 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,392 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023. F17 · price: Represents volume-weighted average price of sales of 4 shares of Company stock on February 1, 2024 at prices ranging from $961.00 to $961.79. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 1, 2024 at each separate price. Read SEC document |
| February 01, 2024 Filed Feb 5, 2024 21:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 10 | $960.52 | $9,605.20 |
DisclosureSEC source: 0001968202-24-000048 · edgardoc.xml · nonDerivative · entry 18 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,396 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023. F16 · price: Represents volume-weighted average price of sales of 10 shares of Company stock on February 1, 2024 at prices ranging from $960.18 to $960.93. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 1, 2024 at each separate price. Read SEC document |
| February 01, 2024 Filed Feb 5, 2024 21:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 8 | $959.68 | $7,677.44 |
DisclosureSEC source: 0001968202-24-000048 · edgardoc.xml · nonDerivative · entry 17 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,406 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023. F15 · price: Represents volume-weighted average price of sales of 8 shares of Company stock on February 1, 2024 at prices ranging from $959.14 to $959.95. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 1, 2024 at each separate price. Read SEC document |
| February 01, 2024 Filed Feb 5, 2024 21:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 5 | $958.65 | $4,793.25 |
DisclosureSEC source: 0001968202-24-000048 · edgardoc.xml · nonDerivative · entry 16 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,414 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023. F14 · price: Represents volume-weighted average price of sales of 5 shares of Company stock on February 1, 2024 at prices ranging from $958.48 to $958.90. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 1, 2024 at each separate price. Read SEC document |
| February 01, 2024 Filed Feb 5, 2024 21:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 3 | $957.75 | $2,873.25 |
DisclosureSEC source: 0001968202-24-000048 · edgardoc.xml · nonDerivative · entry 15 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,419 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023. F13 · price: Represents volume-weighted average price of sales of 3 shares of Company stock on February 1, 2024 at prices ranging from $957.32 to $957.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 1, 2024 at each separate price. Read SEC document |
| February 01, 2024 Filed Feb 5, 2024 21:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 7 | $956.21 | $6,693.47 |
DisclosureSEC source: 0001968202-24-000048 · edgardoc.xml · nonDerivative · entry 14 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,422 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023. F12 · price: Represents volume-weighted average price of sales of 7 shares of Company stock on February 1, 2024 at prices ranging from $956.00 to $956.41. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 1, 2024 at each separate price. Read SEC document |
| February 01, 2024 Filed Feb 5, 2024 21:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 10 | $955.35 | $9,553.50 |
DisclosureSEC source: 0001968202-24-000048 · edgardoc.xml · nonDerivative · entry 13 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,429 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023. F11 · price: Represents volume-weighted average price of sales of 10 shares of Company stock on February 1, 2024 at prices ranging from $955.11 to $955.62. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 1, 2024 at each separate price. Read SEC document |
| February 01, 2024 Filed Feb 5, 2024 21:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 5 | $954.52 | $4,772.60 |
DisclosureSEC source: 0001968202-24-000048 · edgardoc.xml · nonDerivative · entry 12 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,439 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023. F10 · price: Represents volume-weighted average price of sales of 5 shares of Company stock on February 1, 2024 at prices ranging from $954.15 to $954.91. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 1, 2024 at each separate price. Read SEC document |
| February 01, 2024 Filed Feb 5, 2024 21:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 3 | $953.18 | $2,859.54 |
DisclosureSEC source: 0001968202-24-000048 · edgardoc.xml · nonDerivative · entry 11 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,444 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023. F9 · price: Represents volume-weighted average price of sales of 3 shares of Company stock on February 1, 2024 at prices ranging from $953.12 to $953.26. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 1, 2024 at each separate price. Read SEC document |
| February 01, 2024 Filed Feb 5, 2024 21:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 3 | $951.40 | $2,854.20 |
DisclosureSEC source: 0001968202-24-000048 · edgardoc.xml · nonDerivative · entry 10 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,447 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023. F8 · price: Represents volume-weighted average price of sales of 3 shares of Company stock on February 1, 2024 at prices ranging from $951.10 to $951.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 1, 2024 at each separate price. Read SEC document |
| February 01, 2024 Filed Feb 5, 2024 21:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 2 | $950.01 | $1,900.02 |
DisclosureSEC source: 0001968202-24-000048 · edgardoc.xml · nonDerivative · entry 9 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,450 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023. F7 · price: Represents volume-weighted average price of sales of 2 shares of Company stock on February 1, 2024 at prices ranging from $950.00 to $950.02. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 1, 2024 at each separate price. Read SEC document |
| February 01, 2024 Filed Feb 5, 2024 21:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 10 | $949.48 | $9,494.80 |
DisclosureSEC source: 0001968202-24-000048 · edgardoc.xml · nonDerivative · entry 8 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,452 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023. F6 · price: Represents volume-weighted average price of sales of 10 shares of Company stock on February 1, 2024 at prices ranging from $949.13 to $949.81. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 1, 2024 at each separate price. Read SEC document |
| February 01, 2024 Filed Feb 5, 2024 21:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1 | $948.77 | $948.77 |
DisclosureSEC source: 0001968202-24-000048 · edgardoc.xml · nonDerivative · entry 7 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,462 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023. Read SEC document |
| February 01, 2024 Filed Feb 5, 2024 21:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 3 | $947.37 | $2,842.11 |
DisclosureSEC source: 0001968202-24-000048 · edgardoc.xml · nonDerivative · entry 6 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,463 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023. F5 · price: Represents volume-weighted average price of sales of 3 shares of Company stock on February 1, 2024 at prices ranging from $947.16 to $947.64. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 1, 2024 at each separate price. Read SEC document |
| February 01, 2024 Filed Feb 5, 2024 21:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1 | $944.66 | $944.66 |
DisclosureSEC source: 0001968202-24-000048 · edgardoc.xml · nonDerivative · entry 5 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,466 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023. Read SEC document |
| February 01, 2024 Filed Feb 5, 2024 21:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 3 | $943.54 | $2,830.62 |
DisclosureSEC source: 0001968202-24-000048 · edgardoc.xml · nonDerivative · entry 4 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,467 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023. F4 · price: Represents volume-weighted average price of sales of 3 shares of Company stock on February 1, 2024 at prices ranging from $943.49 to $943.65. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 1, 2024 at each separate price. Read SEC document |
| February 01, 2024 Filed Feb 5, 2024 21:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 5 | $942.50 | $4,712.50 |
DisclosureSEC source: 0001968202-24-000048 · edgardoc.xml · nonDerivative · entry 3 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,470 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023. F3 · price: Represents volume-weighted average price of sales of 5 shares of Company stock on February 1, 2024 at prices ranging from $942.03 to $942.96. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 1, 2024 at each separate price. Read SEC document |
| February 01, 2024 Filed Feb 5, 2024 21:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 6 | $941.91 | $5,651.46 |
DisclosureSEC source: 0001968202-24-000048 · edgardoc.xml · nonDerivative · entry 2 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,475 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023. F2 · price: Represents volume-weighted average price of sales of 6 shares of Company stock on February 1, 2024 at prices ranging from $941.83 to $941.96. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 1, 2024 at each separate price. Read SEC document |
| February 01, 2024 Filed Feb 5, 2024 21:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1 | $939.53 | $939.53 |
DisclosureSEC source: 0001968202-24-000048 · edgardoc.xml · nonDerivative · entry 1 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,481 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 21:08 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 1,607 | $0.00 Strike: $888.34 | $0.00 |
DisclosureSEC source: 0001968202-24-000025 · edgardoc.xml · derivative · entry 15 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,607 Underlying: Common Stock · 1,607 shares Expires 2034-01-02 F12 · derivative.exercise_date: On the date of the Company's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 21:08 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantCommon Stock | 135 | $0.00 | $0.00 |
DisclosureSEC source: 0001968202-24-000025 · edgardoc.xml · nonDerivative · entry 14 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,482 F11 · kind: Reflects an acquisition of time-based vesting restricted stock units each representing a contingent right to receive one share of the Company's common stock. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 21:08 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 3 | $904.49 | $2,713.47 |
DisclosureSEC source: 0001968202-24-000025 · edgardoc.xml · nonDerivative · entry 13 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,347 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023. F10 · price: Represents volume-weighted average price of sales of 3 shares of Company stock on January 2, 2024 at prices ranging from $904.00 to $904.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on January 2, 2024 at each separate price. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 21:08 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 13 | $903.49 | $11,745.37 |
DisclosureSEC source: 0001968202-24-000025 · edgardoc.xml · nonDerivative · entry 12 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,350 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023. F9 · price: Represents volume-weighted average price of sales of 13 shares of Company stock on January 2, 2024 at prices ranging from $903.13 to $903.93. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on January 2, 2024 at each separate price. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 21:08 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 10 | $902.37 | $9,023.70 |
DisclosureSEC source: 0001968202-24-000025 · edgardoc.xml · nonDerivative · entry 11 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,363 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023. F8 · price: Represents volume-weighted average price of sales of 10 shares of Company stock on January 2, 2024 at prices ranging from $902.14 to $902.92. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on January 2, 2024 at each separate price. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 21:08 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 9 | $901.46 | $8,113.14 |
DisclosureSEC source: 0001968202-24-000025 · edgardoc.xml · nonDerivative · entry 10 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,373 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023. F7 · price: Represents volume-weighted average price of sales of 9 shares of Company stock on January 2, 2024 at prices ranging from $901.03 to $901.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on January 2, 2024 at each separate price. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 21:08 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 29 | $900.59 | $26,117.11 |
DisclosureSEC source: 0001968202-24-000025 · edgardoc.xml · nonDerivative · entry 9 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,382 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023. F6 · price: Represents volume-weighted average price of sales of 29 shares of Company stock on January 2, 2024 at prices ranging from $900.00 to $900.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on January 2, 2024 at each separate price. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 21:08 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 14 | $899.66 | $12,595.24 |
DisclosureSEC source: 0001968202-24-000025 · edgardoc.xml · nonDerivative · entry 8 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,411 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023. F5 · price: Represents volume-weighted average price of sales of 14 shares of Company stock on January 2, 2024 at prices ranging from $899.08 to $899.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on January 2, 2024 at each separate price. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 21:08 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 6 | $898.76 | $5,392.56 |
DisclosureSEC source: 0001968202-24-000025 · edgardoc.xml · nonDerivative · entry 7 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,425 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023. F4 · price: Represents volume-weighted average price of sales of 6 shares of Company stock on January 2, 2024 at prices ranging from $898.45 to $898.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on January 2, 2024 at each separate price. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 21:08 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 3 | $897.41 | $2,692.23 |
DisclosureSEC source: 0001968202-24-000025 · edgardoc.xml · nonDerivative · entry 6 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,431 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023. F3 · price: Represents volume-weighted average price of sales of 3 shares of Company stock on January 2, 2024 at prices ranging from $897.35 to $897.54. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on January 2, 2024 at each separate price. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 21:08 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 8 | $896.47 | $7,171.76 |
DisclosureSEC source: 0001968202-24-000025 · edgardoc.xml · nonDerivative · entry 5 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,434 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023. F2 · price: Represents volume-weighted average price of sales of 8 shares of Company stock on January 2, 2024 at prices ranging from $896.21 to $896.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on January 2, 2024 at each separate price. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 21:08 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1 | $892.00 | $892.00 |
DisclosureSEC source: 0001968202-24-000025 · edgardoc.xml · nonDerivative · entry 4 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,442 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 21:08 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1 | $887.13 | $887.13 |
DisclosureSEC source: 0001968202-24-000025 · edgardoc.xml · nonDerivative · entry 3 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,443 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 21:08 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 2 | $886.26 | $1,772.52 |
DisclosureSEC source: 0001968202-24-000025 · edgardoc.xml · nonDerivative · entry 2 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,444 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 21:08 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1 | $873.91 | $873.91 |
DisclosureSEC source: 0001968202-24-000025 · edgardoc.xml · nonDerivative · entry 1 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,446 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023. Read SEC document |
| December 01, 2023 Filed Dec 4, 2023 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 2 | $827.61 | $1,655.22 |
DisclosureSEC source: 0001968202-23-000044 · edgardoc.xml · nonDerivative · entry 19 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,447 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023. F16 · price: Represents volume-weighted average price of sales of 2 shares of Company stock on December 1, 2023 at prices ranging from $827.22 to $827.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 1, 2023 at each separate price. Read SEC document |
| December 01, 2023 Filed Dec 4, 2023 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 10 | $826.62 | $8,266.20 |
DisclosureSEC source: 0001968202-23-000044 · edgardoc.xml · nonDerivative · entry 18 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,449 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023. F15 · price: Represents volume-weighted average price of sales of 10 shares of Company stock on December 1, 2023 at prices ranging from $826.10 to $826.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 1, 2023 at each separate price. Read SEC document |
| December 01, 2023 Filed Dec 4, 2023 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 2 | $825.38 | $1,650.76 |
DisclosureSEC source: 0001968202-23-000044 · edgardoc.xml · nonDerivative · entry 17 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,459 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023. F14 · price: Represents volume-weighted average price of sales of 2 shares of Company stock on December 1, 2023 at prices ranging from $825.05 to $825.71. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 1, 2023 at each separate price. Read SEC document |
| December 01, 2023 Filed Dec 4, 2023 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 3 | $824.66 | $2,473.98 |
DisclosureSEC source: 0001968202-23-000044 · edgardoc.xml · nonDerivative · entry 16 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,461 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023. F13 · price: Represents volume-weighted average price of sales of 3 shares of Company stock on December 1, 2023 at prices ranging from $824.52 to $824.94. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 1, 2023 at each separate price. Read SEC document |
| December 01, 2023 Filed Dec 4, 2023 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 6 | $823.36 | $4,940.16 |
DisclosureSEC source: 0001968202-23-000044 · edgardoc.xml · nonDerivative · entry 15 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,464 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023. F12 · price: Represents volume-weighted average price of sales of 6 shares of Company stock on December 1, 2023 at prices ranging from $823.06 to $823.65. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 1, 2023 at each separate price. Read SEC document |
| December 01, 2023 Filed Dec 4, 2023 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1 | $822.49 | $822.49 |
DisclosureSEC source: 0001968202-23-000044 · edgardoc.xml · nonDerivative · entry 14 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,470 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.